balsalazide (colazal) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Balsalazide, a prodrug that is enzymatically cleaved by bacterial azoreduction to release equimolar quantities of mesalamine (5-aminosalicylic acid or 5-ASA) in the colon, an anti-inflammatory drug. The mechanism of action of 5-ASA is unknown, but appears to be local to the colonic mucosa rather than systemic. Balsalazide is indicated for the treatment of mildly to moderately active ulcerative colitis. Most frequently reported adverse events are: headache, abdominal pain, diarrhea, nausea, vomiting, respiratory infection, and arthralgia. The use of orally administered antibiotics could, theoretically, interfere with the release of mesalamine in the colon.   NCATS

Chemistry

  • SMILES: O=C(O)CCNC(=O)c1ccc(/N=N/c2ccc(O)c(C(=O)O)c2)cc1
  • InChIKey: IPOKCKJONYRRHP-FMQUCBEESA-N
  • Mol. Mass: 357.32
  • ALogP: 2.71
  • ChEMBL Molecules:
    balsalazide  
    balsalazide disodium  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$0.2197 - $2.5704

Australia

$0.3965
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

3-(2-{4-[(2-carboxyethyl)carbamoyl]phenyl}hydrazinylidene)-6-oxocyclohexa-1,4-diene-1-carboxylic acid | 5-[4-(2-carboxy-ethylcarbamoyl)-phenylazo]-2-hydroxy-benzoic acid | 5-(carboxyethylcarbamoyl-4-phenylazo)salicylic acid | balsalazid | balsalazida | balsalazide | balsalazide disodium | balsalazide sodium | balsalazido | balsalazidum | balsalazine | benzoic acid, 5-((4-(((2-carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxy-, disodium salt | bx661a | bx 661a | bx-661a | colazal | colazide | (e)-5-((4-(((2-carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxybenzoic acid | (e)-5-({p-[(2-carboxyethyl)carbamoyl]phenyl}azo)-2-salicylic acid | giazo

Organizations (14)

Research & Development (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (11)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (4)

Approved Indications (2)


 

Colitis, Ulcerative (approved 2000)

Crohn Disease

Experimental Indications - Clinical Trial Phases 1-4 (3)


 

Colitis, Ulcerative (Phase 3)

Healthy Volunteers (Phase 1)

Inflammatory Bowel Diseases (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial Organizations: 5

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue